Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its primary product, CARDAMYST (etripamil) nasal spray, is an FDA-approved prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) and is seeking regulatory approval in regions outside the United States, including China and Europe. Etripamil is a novel, rapid-onset, non-dihydropyridine calcium channel blocker designed for patient self-administration outside of medical settings. The company utilizes a global supply chain to manufacture the active pharmaceutical ingredient and assemble the nasal spray delivery device, distributing the product via third-party logistics providers to wholesalers and retail pharmacies in the United States.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage milestonepharma.com
Sector Healthcare IR page investors.milestonepharma.com
Tags
cardiovascular, arrhythmia, nasal spray, calcium channel blocker, self-administration, psvt, atrial fibrillation, CARDAMYST, etripamil
Press page —

Metrics

Valuation  
Market cap $ 107.779M
Market cap (USD) $ 107.779M
P/E -1.22
PEG —
P/BV -17.34
P/S 69.71
P/OCF -1.40
P/FCF -1.40
Dividend yield —
Turnover / mcap —
Returns  
ROE -229.7%
ROI -63.7%
ROIC -47.1%
Profit margin -4,078.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 63
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 1.546M — 1M 5M 15M — — —
Net profit -63.058M -41.519M -59.685M -58.388M -42.853M -49.967M -55.229M -23.185M
Free cash flow -49.343M -28.881M -46.536M -52.741M -33.224M — -51.565M -21.051M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 2.02 2.36 1.67 3.96 6.55 6.7 16.01 —
Price performance 12m -0.14 0.41 -0.58 -0.4 -0.02 -0.58 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 514,000 941,000 698,000 2.49M 2M 1.45M 1.19M
Cash and deposits (USD) 10.9M 85.9M 120M 72.3M 114M 7.64M 13.8M 25.3M 73M
Right-of-use assets (USD) — 321,000 524,000 980,000 711,000 2.42M 1.92M 1.38M 1.13M
Cash flow detail
Operating cash flow (USD) — -21M -51.2M -50.7M -33.2M -52.5M -46.4M -28.8M -49M
Purchases of property, plant and equipment (USD) — -5,000 -413,000 — — -272,000 -112,000 -33,000 -302,000
Change in inventories (cash effect) (USD) — — — — — — — — -648,000
Change in payables (cash effect) (USD) — 2.88M 3.52M -2.08M 637,000 -907,000 1.04M 875,000 4.43M
Share-based compensation (USD) — 633,000 1.19M 4.95M 7.28M 9.05M 9.53M 5.78M 7.46M
Free cash flow (OCF - PPE - intangibles) (USD) — -21.1M -51.6M — — -52.7M -46.5M -28.9M -49.3M
Income detail
Research and development expense (USD) — 16.8M 42M 34.5M 38.7M 39.8M 31.1M 14.4M 18.1M
↳ 5y CAGR +13.0% -19.3% -12.1%
Reported Jun 19, 2019 Mar 6, 2020 Mar 6, 2020 Mar 29, 2021 Mar 24, 2022 Mar 29, 2023 Mar 21, 2024 Mar 13, 2025 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Launch of CARDAMYST® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage

Company is reducing operating expenses by approximately 30% while prioritizing sales force efforts for CARDAMYST; expects cash runway into late 2028

AFib-RVR Phase 3 trial on schedule with data expected in 2H 2028

MONTREAL and CHARLOTTE, N.C., -- November 13, 2026 – Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the quarter ended September 30, 2026, and announced cost-efficiency measures designed to extend cash runway through the topline results from its Phase 3 trial of etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR), while preserving the sales force and core commercial activities for CARDAMYST® (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

On October 23, 2026, Milestone Pharmaceuticals Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common shares was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market, as the minimum bid price of the Company’s common shares was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 21, 2027, to regain compliance with the rule referred to in this paragraph. To regain compliance, during this 180-day compliance period, the Company’s minimum bid price of listed securities must close at $1.00 per share or more for a minimum of 10 consecutive business days. The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Select Market.

October 19, 2026

PDF Version

MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data and program updates for CARDAMYST® (etripamil) nasal spray for its approved PSVT indication and on etripamil nasal spray for an investigational indication will be presented at three upcoming cardiovascular medical meetings:

Presentation Details

| Cardiology Advanced Practice Providers (CAPP) National Conference |

| Title: | Minimal Blood Pressure Effects of Intranasal Etripamil for PSVT |

| Presenter: | Adriane Atkins, ND, Milestone Pharmaceuticals |

| Day/Time: | Thursday, October 22, 6:45 pm CT |

| Location: | Hyatt Regency Dallas, Dallas, TX |

| | |

| Title: | A Multicenter, Placebo-Controlled, Phase 3 Study of Etripamil in Patients with Atrial Fibrillation and Rapid Ventricular Rate: ReVeRA-301 Trial Design |

| Presenter: | Rachel Swearingen, PharmD, Milestone Pharmaceuticals |

| Day/Time: | Thursday, October 22, 6:45 pm CT |

| Location: | Hyatt Regency Dallas, Dallas, TX |

| Transcatheter Cardiovascular Therapeutics (TCT) 2026 |

| Title: | Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute PSVT Across Multiple Clinical Trials |

| Presenter: | David Bharucha, MD, Ph.D., FACC, Chief Medical Officer, Milestone Pharmaceuticals |

| Day/Time: | Monday, November 2, 12:00 pm PT |

| Location: | San Diego Convention Center, San Diego, CA |

| | |

| American Heart Association (AHA) Scientific Sessions 2026 |

| Title: | Use of Etripamil in the RAPID Study for Recurrent PSVT After Prior Ablation |

| Presenter: | David Bharucha, MD, Ph.D., FACC, Chief Medical Officer, Milestone Pharmaceuticals |

| Day/Time: | Saturday, November 7, 12:50 pm CT |

| Location: | McCormick Place Convention Center**,**Chicago, IL |

About CARDAMYST

CARDAMYST® (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit CARDAMYST.com.

U.S. FDA Indication CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?

CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

  • are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.

  • have limitations in activities due to heart failure (moderate to severe heart failure).

  • have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).

  • have sick sinus syndrome without a permanent pacemaker.

  • have second degree or higher atrioventricular (AV) block.

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of fainting.

  • have low blood pressure.

  • are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.

  • are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.

**Tell your healthcare provider about all the medicines you take,**including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

  • Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.

The most common side effects of CARDAMYST include:

| * nasal discomfort * nasal congestion * runny nose | * throat irritation * nosebleed |

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/.

Prompts

Milestone Pharmaceuticals Inc. (ticker MIST), listed in United States.

ETFs Holding Milestone Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
SURI 2.03% 3,349,379 $ 1.384M Nov 17, 2026